Lymphoma patients get continued access to promising drug

NCT ID NCT05688475

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 21 times

Summary

This study offers ongoing CC-122 treatment to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor safety and side effects over the long term. It is not a cure, but aims to keep the disease under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 100

New York, New York, 10065, United States
Local Institution - 101

Nashville, Tennessee, 37203, United States
Local Institution - 102

Madison, Wisconsin, 53792, United States
Local Institution - 300

Bordeaux, 33076, France
Local Institution - 301

Marseille, 13273, France
Local Institution - 400

Amsterdam, 1105, Netherlands
Local Institution - 500

Koto-ku, Tokyo, 1358550, Japan

Conditions

Explore the condition pages connected to this study.

NON HODGKIN LYMPHOMA